{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:17:35Z","timestamp":1789975055074,"version":"4.0.1"},"reference-count":68,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T00:00:00Z","timestamp":1461283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI087746"],"award-info":[{"award-number":["AI087746"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"S & T Global, Inc.","award":["Special Funding Project 2179"],"award-info":[{"award-number":["Special Funding Project 2179"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0152036","type":"journal-article","created":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T13:35:40Z","timestamp":1461332140000},"page":"e0152036","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175"],"prefix":"10.1371","volume":"11","author":[{"given":"Philippe A.","family":"Gallay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udayan","family":"Chatterji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Bobardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,4,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/j.gastro.2005.11.010","article-title":"American Gastroenterological Association technical review on the management of hepatitis C","volume":"130","author":"JL Dienstag","year":"2006","journal-title":"Gastroenterology"},{"key":"ref2","first-page":"2436","article-title":"World journal of gastroenterology","volume":"13","author":"MJ Alter","year":"2007","journal-title":"WJG"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14728214.13.1.1","article-title":"Emerging drugs for hepatitis C","volume":"13","author":"V Soriano","year":"2008","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"CW Shepard","year":"2005","journal-title":"The Lancet infectious diseases"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"GL Armstrong","year":"2006","journal-title":"Annals of internal medicine"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/pgmj.2008.068205","article-title":"Current and future management of chronic hepatitis C infection","volume":"84","author":"TJ Cross","year":"2008","journal-title":"Postgraduate medical journal"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: efficacy, side effects, and complications","volume":"55","author":"MP Manns","year":"2006","journal-title":"Gut"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7150\/ijms.3.41","article-title":"Epidemiology of hepatitis C virus (HCV) infection","volume":"3","author":"T Sy","year":"2006","journal-title":"International journal of medical sciences"},{"key":"ref9","first-page":"747","article-title":"Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial","volume":"26","author":"MJ Tong","year":"1997","journal-title":"Consensus Interferon Study Group. Hepatology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0034-1371007","article-title":"New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development","volume":"34","author":"JM Pawlotsky","year":"2014","journal-title":"Semin Liver Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/M14-1336","article-title":"Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States","volume":"162","author":"J Chhatwal","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref12","unstructured":"U.S. Food and Drug Administration. SOVALDITM (sofosbuvir) prescribing information. 2014. Available at: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204671s000lbl.pdf\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204671s000lbl.pdf<\/ext-link>. Accessed on January 3, 2015."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"S Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"ref14","article-title":"Therapy: Avoiding treatment failures associated with HCV resistance","author":"JM Pawlotsky","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/apt.13342","article-title":"Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-na\u00efve patients with chronic HCV genotype 1 infection (ESSENTIAL II)","volume":"42","author":"S Zeuzem","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"DR Nelson","year":"2015","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.27960","article-title":"Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection","volume":"62","author":"JM Pawlotsky","year":"2015","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/jvh.12360","article-title":"Alisporivir with peginterferon\/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial","volume":"22","author":"M Buti","year":"2015","journal-title":"J Viral Hepat"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.22131","article-title":"The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus","volume":"47","author":"R Flisiak","year":"2008","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22835","article-title":"The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-na\u00efve hepatitis C patients","volume":"49","author":"R Flisiak","year":"2009","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1128\/AAC.00016-14","article-title":"The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance","volume":"58","author":"U Chatterji","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"ref22","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1016\/S0168-8278(15)30073-8","article-title":"Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir","volume":"62","author":"H Dvory-Sobol","year":"2015","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"ref23","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/S0168-8278(15)30071-4","article-title":"Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir\/r-, ombitasvir- and dasabuvir-based regimens","volume":"62","author":"P Krishnan","year":"2015","journal-title":"J Hepatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0167-4838(84)90285-1","article-title":"Conformational specificity of chymotrypsin toward proline-containing substrates","volume":"791","author":"G Fischer","year":"1984","journal-title":"Biochim Biophys Acta"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1021\/bi00239a007","article-title":"Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay","volume":"30","author":"JL Kofron","year":"1991","journal-title":"Biochemistry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1128\/AAC.01324-07","article-title":"Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent","volume":"52","author":"RG Ptak","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"ref27","first-page":"43","article-title":"Cyclosporine and its analogue SDZ IMM 125 mediate very similar effects on T-cell activation\u2014a comparative analysis in vitro","volume":"24","author":"G Baumann","year":"1992","journal-title":"Transplant Proc"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1128\/AAC.00289-10","article-title":"Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a","volume":"54","author":"M Robinson","year":"2010","journal-title":"Antimicrob. Agents Chemother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0166-0934(03)00134-4","article-title":"A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C","volume":"110","author":"JM Vrolijk","year":"2003","journal-title":"J. Virol. Methods"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e88866","DOI":"10.1371\/journal.pone.0088866","article-title":"HCV core residues critical for infectivity are also involved in core-NS5A complex formation","volume":"9","author":"K Gawlik","year":"2014","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"T Wakita","year":"2005","journal-title":"Nat. Med."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1128\/JVI.02460-05","article-title":"Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses","volume":"80","author":"G Koutsoudakis","year":"2006","journal-title":"J. Virol."},{"key":"ref33","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1128\/AAC.01256-12","article-title":"Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells","volume":"56","author":"M Saeed","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug-drug interactions","volume":"14","author":"MN Prichard","year":"1990","journal-title":"Antiviral Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"16998","DOI":"10.1074\/jbc.M109.007625","article-title":"The isomerase active site of cyclophilin A is critical for hepatitis C virus replication","volume":"284","author":"U Chatterji","year":"2009","journal-title":"J Biol Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1073\/pnas.0801388105","article-title":"Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus","volume":"105","author":"MD Bobardt","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1128\/JVI.02614-07","article-title":"Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro","volume":"82","author":"F Yang","year":"2008","journal-title":"J Virol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e1000546","DOI":"10.1371\/journal.ppat.1000546","article-title":"Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics","volume":"5","author":"A Kaul","year":"2009","journal-title":"PLoS Pathog"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1128\/JVI.02550-08","article-title":"Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex","volume":"83","author":"Z Liu","year":"2009","journal-title":"J Virol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.virol.2009.10.043","article-title":"Multiple cyclophilins involved in different cellular pathways mediate HCV replication","volume":"397","author":"LA Gaither","year":"2010","journal-title":"Virology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1053\/j.gastro.2005.06.031","article-title":"Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins","volume":"129","author":"M Nakagawa","year":"2005","journal-title":"Gastroenterology"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature12427","article-title":"Completion of the entire hepatitis C virus life cycle in genetically humanized mice","volume":"501","author":"M Dorner","year":"2013","journal-title":"Nature"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jhep.2010.01.041","article-title":"HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors","volume":"53","author":"U Chatterji","year":"2010","journal-title":"J Hepatol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1128\/AAC.00693-12","article-title":"The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes","volume":"56","author":"S Hopkins","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1128\/AAC.00919-12","article-title":"Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir","volume":"56","author":"JA Garcia-Rivera","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e1001118","DOI":"10.1371\/journal.ppat.1001118","article-title":"A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach","volume":"6","author":"F Yang","year":"2010","journal-title":"PLoS Pathog"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.3390\/v4123303","article-title":"Subtype specific differences in NS5A domain II reveals involvement of proline at position 310 in cyclosporine susceptibility of hepatitis C virus","volume":"4","author":"IU Ansari","year":"2012","journal-title":"Viruses"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1128\/JVI.06641-11","article-title":"A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility","volume":"86","author":"H Gris\u00e9","year":"2012","journal-title":"J Virol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.virol.2012.11.018","article-title":"Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility","volume":"436","author":"IU Ansari","year":"2013","journal-title":"Virology"},{"key":"ref50","unstructured":"Tiongyip C, Jones CT, Tang Y, Snoeck J, Vandamme AM, Coelmont L, et al. (2011) Host targeting cyclophilin inhibitor alisporivir presents a high barrier to resistance with no cross-resistance to direct acting antivirals. 6th International Workshop on Hepatitis C, Resistance and New Compounds. Cambridge, MA, June 24th."},{"key":"ref51","doi-asserted-by":"crossref","first-page":"e13687","DOI":"10.1371\/journal.pone.0013687","article-title":"DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A","volume":"5","author":"L Coelmont","year":"2010","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.chembiol.2014.10.023","article-title":"Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection","volume":"22","author":"MJ Hansson","year":"2015","journal-title":"Chem Biol"},{"issue":"20","key":"ref53","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1074\/jbc.M809244200","article-title":"Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis\/trans isomerase activity of cyclophilins A and B","volume":"284","author":"X Hanoulle","year":"2009","journal-title":"J Biol Chem"},{"key":"ref54","article-title":"Inhibition of HCV Replication by Cyclophilin Antagonists is Linked to Replication Fitness and Occurs by Inhibition of Membranous Web Formation","author":"V Madan","year":"2014","journal-title":"Gastroenterology"},{"key":"ref55","article-title":"Cyclophilin and NS5A Inhibitors, but not other Anti-HCV Agents, Preclude HCV-Mediated Formation of Double Membrane Vesicle Viral Factories","author":"U Chatterji","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"e0134707","DOI":"10.1371\/journal.pone.0134707","article-title":"The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action","volume":"10","author":"PA Gallay","year":"2015","journal-title":"PLoS One"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"e1003056","DOI":"10.1371\/journal.ppat.1003056","article-title":"Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication","volume":"8","author":"I Romero-Brey","year":"2012","journal-title":"PLoS Pathog"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"10612","DOI":"10.1128\/JVI.01370-13","article-title":"Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment","volume":"87","author":"D Paul","year":"2013","journal-title":"J Virol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1099\/vir.0.022186-0","article-title":"Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes","volume":"91","author":"P Ferraris","year":"2010","journal-title":"J Gen Virol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1053\/j.gastro.2014.07.019","article-title":"Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication","volume":"147","author":"C Berger","year":"2014","journal-title":"Gastroenterology"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1053\/j.gastro.2014.09.024","article-title":"HCV NS5A inhibitors disrupt replication factory formation: a novel mechanism of antiviral action","volume":"147","author":"NS Eyre","year":"2014","journal-title":"Gastroenterology"},{"issue":"53","key":"ref62","doi-asserted-by":"crossref","first-page":"44249","DOI":"10.1074\/jbc.M112.392209","article-title":"Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A","volume":"287","author":"C Rosnoblet","year":"2012","journal-title":"J Biol Chem"},{"issue":"4","key":"ref63","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","article-title":"Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor","volume":"60","author":"S Nkongolo","year":"2014","journal-title":"J Hepatol"},{"issue":"3","key":"ref64","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbrc.2013.12.052","article-title":"Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP","volume":"443","author":"M Iwamoto","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.gastro.2014.10.004","article-title":"Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production","volume":"148","author":"S Phillips","year":"2015","journal-title":"Gastroenterology"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/nm910","article-title":"Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors","volume":"9","author":"GJ Towers","year":"2003","journal-title":"Nat Med"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"12800","DOI":"10.1128\/JVI.78.23.12800-12808.2004","article-title":"Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity","volume":"78","author":"E Sokolskaja","year":"2004","journal-title":"J Virol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1093\/nar\/gkh715","article-title":"Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A","volume":"32","author":"S Liu","year":"2004","journal-title":"Nucleic Acids Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0152036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:54:44Z","timestamp":1540342484000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0152036"}},"subtitle":[],"editor":[{"given":"Gualtiero","family":"Alvisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,4,22]]},"references-count":68,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0152036","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,22]]}}}